2results about How to "Non-immunogenic" patented technology

This invention belongs to the field of molecular biology and medical detection technology, and discloses a bladder cancer-specific nucleic acid aptamer, nucleic acid aptamer derivatives, and their applications. The nucleotide sequences of the nucleic acid aptamer are shown in SEQ ID NO: 1, 2, and 3. This invention screened three monoclonal nucleic acid aptamer DNA chains from bladder cancer tissue samples using the exponential enrichment systematic evolution (SELEX) technique and identified two target proteins that bind to these three nucleic acid aptamers. The nucleic acid aptamers specifically target the target proteins CAPRIN1 and FXR1 on the surface of bladder tumor cells. The nucleic acid aptamers obtained by this invention have advantages such as high affinity and specificity, no immunogenicity, simple chemical synthesis, stability, and ease of storage and labeling, providing a new molecular tool for the early diagnosis and targeted therapy of bladder cancer.

The invention discloses a recombinant humanized XVII type collagen COL1502 and a preparation method thereof, and belongs to the technical field of genetic engineering. The amino acid sequence of the protein is as shown in SEQ ID NO.2, and the coding gene sequence of the protein comprises a sequence as shown in SEQ ID NO.4 or SEQ ID NO.5. The preparation method comprises the following steps: constructing a recombinant bacterium Pichia.pastoris GS115COL1502, and carrying out fermentation culture, purification and the like, so as to obtain the recombinant humanized XVII type collagen COL1502. The protein can realize stable high-yield expression in saccharomycetes, has good biocompatibility, safety and no immunogenicity, can promote cell proliferation and migration, can be widely applied to the fields of medicines, biological materials and the like, and has a wide application prospect.